(Q44019743)

29 November 2017

title

A multicenter evaluation of linezolid antimicrobial activity in North America (English)

1 reference

29 November 2017

1 reference

2

Ronald N Jones

1 reference

29 November 2017

Charles H Ballow

1

1 reference

29 November 2017

Douglas J Biedenbach

series ordinal

3

1 reference

29 November 2017

North American ZAPS Research Group

series ordinal

4

1 reference

29 November 2017

publication date

1 May 2002

1 reference

Diagnostic Microbiology and Infectious Disease

29 November 2017

published in

1 reference

29 November 2017

volume

43

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

75-83

1 reference

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Oxazolidinones: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals. Canadian VRE Surveillance Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Mechanism of action of the oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900334-0

7 January 2021

10.1016/S0732-8893(01)00334-0

Identifiers

DOI

1 reference

29 November 2017

1 reference